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Hepatitis C virus (HCV) is the major cause of non-A non-B hepatitis and a leading cause of liver dysfunction worldwide.
While the current therapy for chronic HCV infection is parenteral administration of type 1 interferon (IFN), only a fraction
of HCV-infected individuals completely respond to treatment. Previous studies have correlated the IFN sensitivity of strain
HCV-1b with mutations within a discrete region of the viral nonstructural 5A protein (NS5A), termed the interferon sensitivity
determining region (ISDR), suggesting that NS5A may contribute to the IFN-resistant phenotype of HCV. To determine the
importance of HCV NS5A and the NS5A ISDR in mediating HCV IFN resistance, we tested whether the NS5A protein could
regulate the IFN-induced protein kinase, PKR, a mediator of IFN-induced antiviral resistance and a target of viral and cellular
inhibitors. Using multiple approaches, including biochemical, transfection, and yeast genetics analyses, we can now report
that NS5A represses PKR through a direct interaction with the protein kinase catalytic domain and that both PKR repression
and interaction requires the ISDR. Thus, inactivation of PKR may be one mechanism by which HCV avoids the antiviral
effects of IFN. Finally, the inhibition of the PKR protein kinase by NS5A is the first described function for this HCV protein.
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INTRODUCTION nagle, 1994; Iino et al., 1994). Importantly, type I IFN
is currently the only approved therapy for chronic HCV
HCV, a member of the Flaviviridae (Kato et al., 1990),
infection (Hoofnagle, 1994; Iino et al., 1994).
is the major cause of non-A non-B hepatitis, increasingly
Response to IFN therapy differs among the six HCV
becoming a source of morbidity worldwide (Cuthbert,
genotypes, but is observed, at some level, in all HCV
1994; Mansell and Locarnini, 1995). The HCV virion con-
genotypes worldwide. Of the two predominant HCV ge-
tains a 9.4-kilobase single-stranded positive-sense RNA
notypes, HCV-1a and HCV-1b, the former predominates
genome which encodes a single polyprotein of approxi-
in the Americas and Europe while the latter predomi-
mately 3010 amino acids (aa) that is posttranslationally
nates throughout most Asian countries; both exhibit a
cleaved into individual structural and nonstructural pro-
high level of resistance to IFN therapy (Fried and Hoof-
teins within the infected host cell (Selby et al., 1993; nagle, 1995). Recently, others have sequenced clinical
Shukla et al., 1995; Grakoui et al., 1993). Chronic HCV isolates of the HCV genome and correlated mutations
infection leads to liver cirrhosis in a high frequency of within a discrete region of the nonstructural 5A protein
cases and long-term virus persistence is epidemiologi- (NS5A), termed the IFN sensitivity determining region
cally associated with the development of hepatocellular (ISDR), of HCV-1b with the IFN-sensitive phenotype
carcinoma (Bisceglie, 1995). The public health impact of (shown in Fig. 1A). These studies demonstrated that
chronic HCV infection is currently being realized. In the strains closely matching the prototype HCV-1b NS5A se-
United States alone approximately 3.5 million individuals quence correlated with complete IFN resistance (Eno-
are believed to be infected with HCV, reflected in the moto et al., 1995, 1996).
high frequency of adult liver transplants which are indi- Prior to the current report, possible mechanisms un-
cated due to complications from HCV infection (Alter, derlying this HCV resistance to IFN therapy were un-
1995). This is underscored by the high proportion of HCV- known. The IFN-induced cellular antiviral response is
infected individuals (60–80%) who fail to respond to IFN mediated in part by the actions of the Mx proteins, the
therapy or who relapse after therapy cessation (Hoof- 2*-5* oligoadenylate synthetase, RNAse L, and PKR (re-
view by Sen and Lengyel, 1992; Sen and Ransohoff,
1993). Induced by IFN, these antiviral effector proteins1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (206) 685-0305. E-mail: honey@u.washington.edu. block viral gene expression at multiple levels. Perhaps
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the most widely studied of all the IFN-induced gene prod- and C-terminal coding fragments, each of which lacked
the ISDR. The N-terminal region, encoding amino acidsucts is the PKR protein kinase (Meurs et al., 1990). Acti-
vated by binding to double-stranded RNA (dsRNA), in- 1–236, was amplified by PCR using primer A and primer
C, 5*-CCACTCGAGCGGACAGTTGGCTGG (XhoI sitecluding viral RNAs and regions of secondary RNA struc-
ture, PKR phosphorylates the a subunit of eukaryotic underlined). The C-terminal region, encoding amino
acids 278–447, was amplified using primer B and primertranslation initiation factor 2 (eIF-2a) resulting in a global
cessation of protein synthesis and a concomitant block D, 5*-CCGCTCGAGTGGTGATTCTGGTCTC (XhoI site
underlined). The resulting PCR products were cloned di-in viral replication within the infected cell (Hershey, 1991;
Clemens, 1996; Merrick and Hershey, 1996). To counter- rectly into pCR2.1 to yield pN/CR2.1 and pC/CR2.1, re-
spectively. The N-terminal coding region of NS5A wasact the deleterious effects of IFN induction and PKR acti-
vation, many eukaryotic viruses have evolved mecha- then removed from pN/CR2.1 for insertion into pcDNA3.1/
His to generate pcDNA3.1/His-NS5A 1-236. An ISDR de-nisms to block the activity of PKR, including directing the
physical interaction of PKR with specific kinase inhibitory letion construct was prepared by insertion of the C-termi-
nal coding fragment into the XhoI and XbaI sites ofmolecules (summarized in Fig. 1B) (Katze, 1993, 1995).
Examples include influenza virus which functionally re- pcDNA3.1/His-NS5A 1–236 to generate pcDNA3.1/His-
DISDR. This construct encodes NS5A amino acids 1–cruits the cellular PKR inhibitor, P58IPK, that binds to PKR
to block kinase activity (Gale et al., 1996; Lee et al., 1990, 236 fused in-frame with amino acids 278–447, deleting
the entire ISDR. The insert from pcDNA3.1/His-DISDR1994; Polyak et al., 1996). The virally encoded vaccinia
virus K3L protein, human immunodeficiency virus (HIV), was then subcloned into the 2m yeast expression vectors
pBD and pYES2 to give pBD-DISDR and pYES2-DISDR,Tat protein and adenovirus VAI RNA similarly bind to PKR
to block kinase activity (Gale et al., 1996; Katze et al., respectively. To obtain the NS5A coding region from
HCV-1b, viral RNA was extracted from 100 ml of serum1987; McMillan et al., 1995; Carroll et al., 1993; Beattie
et al., 1991, 1995). (Chomczynski and Sacchi, 1987) obtained under in-
formed consent from a genotype 1b patient who failedThe high frequency of IFN-resistant HCV in the human
population suggests that HCV, like these many other ani- to respond to IFN therapy. Response to IFN was deter-
mined by RT-PCR and bDNA assay, as previously de-mal viruses, has evolved a mechanism(s) to block the
IFN-mediated response to viral infection. Although the scribed (Gretch et al., 1993). Verification of HCV genotype
was determined by a combination of RFLP and genotype-function of NS5A and its role in viral replication had been
unknown, it has been suggested that NS5A, by an ISDR- specific PCR analyses of the viral 5* untranslated region
and sequences encoding the core protein, respectivelydirected mechanism, may mediate IFN resistance by in-
teracting with and repressing one or more IFN-induced (Davidson et al., 1995; Okamoto et al., 1992). Viral cDNA
was synthesized by reverse transcription using the prim-antiviral gene products. In the current report, we now
provide direct proof that NS5A interacts with and inhibits ing oligonucleotide 5* GTGGTGACGCAGCAGAGAGT
(corresponding to nt 7681–7700 of HCV-J (Bukh et al.,the IFN induced protein kinase, PKR. Importantly, we
found that the ISDR was required for NS5A interaction 1995), followed with first-round PCR by the addition of
the upstream primer 5*CAGCCTCACCATCACTCAGCwith PKR and repression of PKR activity. These data thus
provide the first evidence for the molecular mechanisms (corresponding to HCV-J nt 6256–6275). For directional
cloning of NS5A, first-round PCR products were furtherunderlying HCV resistance to IFN therapy.
amplified using the NS5A-specific nested-set oligonucle-
otide primer pair 5*CCTTCCATGGGCTCCGGCTCGT-MATERIALS AND METHODS
GGCTAAAG and 5*ATCGGATCCTTAGGACATTGAGCA-
Plasmid construction
GCAGACGA (NcoI and BamHI sites underlined, respec-
tively). After restriction enzyme digestion, the purifiedTo generate wild-type HCV 1a NS5A constructs, the
complete NS5A coding region from pSPns5 (HCV-1a; a PCR products were cloned into the corresponding sites
of pACT2 (Clontech) to give pAD-NS5A, which encodesgenerous gift from Dr. C. Seeger) was amplified by PCR
using the oligonucleotide primers A, 5*-GGAATTCGAG- an AD-NS5A fusion protein corresponding to HCV-1b.
While the relationship between the ISDR aa sequenceCTCGCCCG and B, 5*-GCTCTAGAAGCACACGACAT-
CTTC (EcoRI and XbaI sites underlined). The resulting of HCV-1a and IFN sensitivity has not been precisely
determined, this region of NS5A (aa 237–276) possessedproduct was directly cloned into pCR2.1 (Invitrogen) to
yield plasmid pNS5A/CR2.1 The NS5A coding region was significant aa identity to the prototypic IFN-resistant ISDR
sequence defined previously (Enomoto et al., 1995, 1996)removed from pNS5A/CR2.1 as an EcoRI fragment for
insertion into pBD (Stratagene) to yield pBD-NS5A, or as and present in our HCV-1b NS5A clone (Fig. 1A). Con-
struction of PKR plasmids pBD-PKR K296R, pAD-PKR aaan EcoRI–XbaI fragment for insertion into pcDNA3.1/His
and pYES2 (Invitrogen), to give pcDNA3.1/His-NS5A and constructs K296R, 1-242, 244-551, 244-366, 367-551, and
pAD-P58IPKwt were described previously (Gale et al.,pYES2-NS5A, respectively. To generate the ISDR deletion
mutant of NS5A, we first generated individual N-terminal 1996). pBD-PKR 98-551 was constructed by recovering
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the 1.6-kb NdeI/BamHI fragment from pET11a-PKR M7 phorylated substrates. We have shown previously that
there is a perfect correlation between phosphorylation(Barber et al., 1995) and cloning it into the corresponding
sites of pGBT10 (Gale et al., 1996). pEMBLYex4-K3L con- of histones and purified eIF-2a by PKR in vitro (Katze et
al., 1991).tains the entire vaccinia virus K3L gene inserted into
pEMBLYex4 and is described in a separate paper (M.
Analysis of protein interaction in vivoKobayashi, E. Locke, J. Silverman, T. Ung, and T. Dever,
manuscript submitted for publication). GST-NS5A was
For analysis of protein interactions in vivo we em-
produced by introducing the BamHI fragment from the
ployed the Saccharomyces cerevisiae strain Hf7c ( MATa
HCV-1a NS5 clone pSPns5 into the plasmid pGEX2T
ura 3-52 his 3-200 lys2-801 ade2-101 trp 1-901 lea2-3,112
(Smith and Johnson, 1988) to give pGST-NS5A. This con-
gal4-542 gal80-538 LYS2: :GAL1-HIS3 URA3: : (GAL4 17-
struct encodes NS5A aa 1–427 fused in frame with the
mers)3-CYC1-lacZ) in a 2-hybrid assay (Fields and Song,glutathione S-transferase protein. The nt sequences of all
1989). For the 2-hybrid assay and the yeast assays de-
constructs used in this study were confirmed by double-
scribed below, cells were transfected by the lithium ace-
stranded DNA sequence analysis using an Applied Bio-
tate method with the indicated expression constructs.
systems automated sequencer.
For 2-hybrid analysis, we first verified expression of all
AD- and BD-fusion proteins in the transfected yeastAnalysis of protein interaction in vitro
clones by immunoblot analysis, using anti-AD or anti-BD
monoclonal antibodies (Clontech) as described by theEscherichia coli harboring pGEX2T or pGST-NS5A
were grown in liquid culture and GST or GST-NS5A ex- manufacturer. In yeast strain Hf7c, synthesis of histidine
is dependent upon interaction of the 2-hybrid proteins.pression was induced by the addition of isopropyl thioga-
lactopryanoside into the culture medium. Bacteria were Thus in the presence of a 2-hybrid protein interaction
strains will exhibit growth on histidine-deficient medium.harvested and extracts prepared for binding analyses
as described previously (Gale et al., 1996). For binding We thereby used the synthesis of the HIS reporter protein
to assay for 2-hybrid protein interaction, as recently de-analyses, we first confirmed expression of GST or GST-
NS5A in our recombinant extracts by immunoblot analy- scribed (Gale et al., 1996). Initial transfectants were se-
lected on SD medium lacking the aa Trp and Leu (/Hissis using either a GST-specific antiserum or an antiserum
specific to a superoxidedismutatse-NS5 fusion protein medium). Transfectants were subsequently streaked
onto SD medium lacking the aa His, Trp, and Leu (0His(anti-NS5; Chiron Corp.). Positive recombinant extracts
were used for in vitro binding analysis. Wild-type human medium) and were grown for 3–6 days to allow depletion
of residual histidine stores. Colonies were restreakedPKR and PKR deletion mutants were in vitro transcribed
from the T7 promoter of pcDNA1neo and translated in onto0His medium and scored for growth after 3–7 days.
We confirmed induction of reporter gene expression inthe presence of [35S]methionine as described previously
(Katze et al., 1991). For in vitro binding analyses, approxi- our 2-hybrid yeast clones (data not shown) by measuring
LacZ expression using a liquid assay and the fluorogenicmately 1 1 105 counts of trichloroacetic acid-precipitable
material from each translation reaction were added to a substrate 4-methylumbelliferyl-b-D-galactoside (MUG) as
described (Cao and Geballe, 1994).crude E. coli extract containing either GST or GST-NS5A
and processed as described (Gale et al., 1996). Labeled
Yeast growth repression assay for determination ofproteins which bound to GST or GST-NS5A were sepa-
NS5A and PKR function in vivorated by SDS–PAGE and visualized by autoradiography
of the dried gel.
For determination of NS5A and PKR function in vivo
we used S. cerevisiae strain RY1-1 (MATa ura3-52 leu2-In vitro assay of PKR function
3 leu2-112 gcn2D trp1-D63 LEU2: : (GAL-CYC1-PKR)2
which carries two copies of human PKR integrated intoFor PKR in vitro kinase assays GST and GST-NS5A
were purified from E. coli extracts using glutathione – the LEU2 locus, under control of the galactose inducible
GAL1-CYC1 promoter (Romano et al., 1995). When grownagarose affinity chromatography. Native PKR was affinity
purified from IFN-treated human 293 cells (Galabru and on inducing medium, this strain exhibits a slow growth
phenotype due to the PKR-mediated phosphorylation ofHovanessian, 1987). The concentration of all purified pro-
teins was assessed by quantitative SDS–PAGE using yeast eIF-2a. Protein expression was verified by immu-
noblot analysis using either an anti-PKR mAb (Laurent etBSA as a standard. In vitro kinase assays were carried
out essentially as described (Tang et al., 1996), except al., 1985) or antisera generated against a recombinant
NS5 protein (a-NS5) (a gift from Chiron). Both NS5A andthat PKR was preincubated with increasing concentra-
tions of GST or GST-NS5A prior to the addition of histone DISDR constructs were efficiently expressed from the
pYes plasmid (data not shown). In addition, we foundsubstrates and [g-32P]ATP. Kinase reaction products
were separated by SDS –PAGE and the dried gel was that coexpression of NS5A or DISDR had no effect on
PKR levels which were expressed efficiently to equalsubjected to autoradiography for visualization of phos-
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levels in both transfected strains (data not shown). To
assess growth of RY1-1 transfectants, yeast colonies
were streaked onto uracil-deficient SD medium and
SGAL medium as described by Romano et al. (1995).
Growth was assessed at 3 –7 days poststreaking of colo-
nies.
Analysis of NS5A function in mammalian cells
To measure the effect of NS5A upon PKR function in
mammalian cells, we used a secreted embryonic alkaline
phosphatase (SEAP) reporter assay (Berger et al., 1988).
pcDNA1neo-SEAP and pcDNA3.1/His-NS5A were co-
transfected into COS1 cells using the DEAE-dextran/
chloroquin method (Cullen, 1987). Details of the SEAP FIG. 1. (A) Top: Amino acid sequence comparison of the prototypic
ISDR of NS5A from IFN-resistant HCV strain J and the correspondingassay (Berger et al., 1988) have been described pre-
region of NS5A from HCV strains 1a and 1b which were used in thisviously by our laboratory (Garfinkel et al., 1993). Trans-
study. Bottom: Structural representation of HCV NS5A representing the
fected cells were maintained in G418-selective medium 447-aa protein from HCV-1a and -1b strains contained in our NS5A
and culture supernatants assayed at 24 hr posttransfec- constructs. The ISDR is indicated in black and is deleted from the
tion for SEAP activity. Cells were subsequently harvested DISDR construct derived from HCV-1a. Amino acid positions within
NS5A are shown above (boldface type), and those corresponding toand extracts prepared for SDS–PAGE and immunoblot
positions within the HCV polyprotein are shown below (normal type).analysis. For immunoblot detection of NS5A expressed
(B) Structural representation of PKR. The positions of the two dsRNA
from pCDNA3.1/His, we used a-NS5 sera. binding motifs within the regulatory domain are shown in black. The
catalytic domain spans aa 265–551 and includes the 11 protein kinase
catalytic domain conservation regions (Hanks et al., 1988) indicated byeIF-2a phosphorylation analysis
roman numerals. The regions of interaction with the PKR-inhibitory
molecules adenovirus VAI RNA, vaccinia virus K3L and P58IPK are indi-To determine the in vivo phosphorylation state of eIF-
cated (Katze et al., 1987; Gale et al., 1996). Also indicated is the NS5A-2a within RY1-1 yeast harboring various expression plas-
binding region (this study).mids, extracts were prepared from the respective strains
and subjected to isoelectric focusing and immunoblot
analyses as described (Dever et al., 1993). Proteins (20 by employing NS5A from HCV 1-a (Fig. 1A) to test the
mg) were first separated by isoelectric focusing and then ability of NS5A to directly interact with PKR. NS5A, ex-
transferred to a nitrocellulose membrane which was sub- pressed as a glutathione S-transferase (GST) fusion pro-
sequently probed with a rabbit polyclonal antiserum spe- tein in E. coli (GST-NS5A), specifically interacted with in
cific to yeast eIF-2a. The relative levels of basal- and vitro translated full-length PKR using a GST pull-down
PKR-phosphorylated eIF-2a from each extract were assay. As seen in Fig. 2A, PKR aa 244–551 were both
quantitated by scanning laser densitometry and are pre- necessary and sufficient for complex formation with GST-
sented as a percentage of the total eIF-2a in a given NS5A. Thus, recombinant NS5A can specifically form a
sample. complex with PKR in vitro which maps to within the pro-
tein kinase catalytic domain-inclusive PKR C-terminus.
RESULTS
NS5A interacts with the PKR protein kinase catalytic
NS5A and PKR interact in vitro domain in vivo
To confirm and extend these results in vivo, we carriedThe mechanism(s) of HCV-mediated IFN resistance
remain unknown, due in part to the inability to propagate out NS5A–PKR interaction studies using the yeast 2-
hybrid system, scoring for growth on histidine-deficientthe virus in cultured cells. However, molecular epidemio-
logic evidence suggests that NS5A may play a role in medium as a positive 2-hybrid protein interaction. For
comparison we included an assessment of the P58IPK –repressing the antiviral affects of IFN during HCV infec-
tion (Enomoto et al., 1995, 1996). This led us to investi- PKR interaction described previously (Gale et al., 1996).
We found that full-length NS5A from an IFN-resistant iso-gate the mechanism of HCV-mediated IFN resistance
and the contribution of NS5A toward establishing the late of strain HCV-1b fused to the GAL4 activation domain
(AD-NS5A) specifically interacted with the inactive full-IFN-resistant phenotype of HCV. We tested the hypothe-
sis that HCV NS5A may possess functions similar to length PKR mutant, PKR K296R, and the truncated mutant
PKR 98-551, each of which were fused to the GAL4 DNAthose of other viral inhibitors of the IFN response (Katze,
1993, 1995), directly repressing the activity of PKR binding domain (BD) (Fig. 2B). BD-PKR 98-551 lacks the
first dsRNA binding domain (Fig. 1B) and is deficient inthrough a physical interaction with the kinase. We began
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FIG. 2. NS5A interacts with PKR. (A) In vitro binding analysis. An autoradiogram of [35S]methionine-labeled PKR in vitro translation products alone
(lanes 1, 4, and 7) or selected by binding to GST or GST-NS5A within crude E. coli extracts, as indicated above each lane. Bound complexes
containing PKR aa 1–551 (lanes 2 and 3), 1–242 (lanes 5 and 6), or 244–551 (lanes 8 and 9) were recovered by selection on glutathione–agarose.
Bound translation products were eluted in SDS sample buffer and separated by 12.5% acrylamide SDS–PAGE. Arrow at right shows the position
of PKR aa 244–551, which migrates slightly faster than the background band visible in lanes 8 and 9. Positions of molecular mass standards are
shown in kDa (left). (B and C) Yeast 2-hybrid analysis. (B) NS5A from HCV-1b interacts with PKR in vivo. Full-length wt NS5A from HCV-1b was
fused to the GAL4 transcription activation domain (AD) and coexpressed in yeast with the GAL4 DNA binding domain (BD) (position 2) or the BD-
PKR fusion constructs BD-PKR K296R and BD-PKR 98-551 (positions 4 and 8, respectively). Coexpression of control GAL4 constructs for the 2-
hybrid assay included AD-vector/BD-vector (position 1), AD-vector/BD-PKR K296R (position 3), AD-P58IPK/BD-PKR K296R (position 5), AD-vector/BD
PKR 98-551 (position 6), and ADP58IPK/BD-PKR 98-551 (position 7). Transfected yeast were streaked onto /His (top) and 0His medium (bottom).
Growth on 0His is indicative of 2-hybrid protein interaction. (C) NS5A from HCV-1a interacts with the PKR protein kinase catalytic domain. Yeasts
expressing either the BD alone (BD-vector) or a BD-NS5A fusion protein from HCV-1a (BD-NS5A) were cotransfected with plasmids expressing the
indicated AD-PKR fusion constructs or the control AD-vector (bottom row), replica plated onto /His (left) and 0His medium (right) and assayed for
growth.
binding dsRNA (Barber et al., 1995). Thus, similar to the We next tested the ability of BD-NS5A, from an HCV-
1a isolate, to interact with AD-PKR in vivo using the 2-cellular PKR inhibitor, P58IPK, HCV-1b NS5A can physi-
cally interact with PKR in vivo. Furthermore, these results hybrid assay. As seen in Fig. 2C, BD-NS5A from HCV
1a specifically interacted with AD-PKR K296R in yeastindicate that the NS5A-PKR interaction is not a dsRNA-
mediated event. cotransfectants, as determined by growth in 0His me-
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dium. Thus, NS5A from the independent strains HCV-1a inhibit the function of PKR in vitro, likely through a direct
effect of the NS5A–PKR interaction.and HCV-1b can physically interact with PKR in vivo. To
map the NS5A-interactive region of PKR, we employed a Expression of PKR in yeast provides an in vivo func-
tional assay for direct measurement of PKR activityseries of AD-PKR mutants to transfect yeast harboring
the HCV 1a BD-NS5A construct. BD-NS5A specifically (Romano et al., 1995). Through its eIF-2a phosphorylat-
ing activity, PKR is growth suppressive when ex-interacted with the PKR catalytic domain, mapping to
within PKR aa 244–366, as AD- constructs PKR 244 – pressed in yeast. Coexpression of PKR with transdomi-
nant inhibitory PKR mutants or virally encoded PKR551 and PKR 244–366 both mediated growth on 0His
medium (Fig. 2C). The NS5A-interactive region of PKR inhibitory proteins, such as HIV Tat or vaccinia virus
K3L, reverses the PKR-mediated slow growth pheno-was exclusive of both the C-terminal 184 aa and the N-
terminal 242 aa, as yeast cotransfectants harboring AD- type in yeast due to in vivo inhibition of PKR and a
concomitant decrease in eIF-2a phosphorylation (Ro-PKR 367–551 and AD-PKR 1–242 failed to grow on 0His
medium. These results indicate that HCV NS5A interacts mano et al., 1995; McMillan et al., 1995; M. Kobayashi,
E. Locke, J. Silverman, T. Ung, and T. Dever, manuscriptwith structures within the PKR protein kinase catalytic
domain in vivo. The NS5A-interactive region of PKR (aa submitted for publication). To assess the effects of
NS5A on PKR function in vivo, we expressed NS5A244–366) includes the region that interacts with the cel-
lular PKR inhibitor, P58IPK (Fig. 1B) (Gale et al., 1996). This under control of the GAL1 galactose-inducible pro-
moter in yeast strain RY1-1, developed by Romano etregion of the protein kinase catalytic domain functions
cooperatively in nucleotide binding and catalysis (Hanks al. (1995). RY1-1 possesses two integrated copies of
human PKR under control of the GAL1-CYC1 galactose-et al., 1988; Bossemeyer, 1995; Taylor et al., 1993). Thus,
similar to the proposed mechanisms of P58IPK-mediated inducible promoter and maintains a PKR-mediated
growth-suppressive phenotype when grown on galac-inhibition of PKR (Gale et al., 1996), formation of an
NS5A–PKR complex may interfere with kinase activation tose medium. For comparison, we included a parallel
analysis of RY1-1 harboring the well-characterized vac-to render PKR nonfunctional.
cinia virus PKR inhibitor, K3L, also under control of
the GAL1-CYC1 promoter (M. Kobayashi, E. Locke, J.NS5A represses PKR function
Silverman, T. Ung and T. Dever, manuscript submitted
for publication). We began our examination of NS5AInhibition of PKR function is critical for establishment
of viral infection. A common theme shared among the function by determining the growth properties of the
RY1-1 transfectants. While all transfectants maintaineddivergent family of virally encoded PKR inhibitors and the
cellular inhibitor, P58IPK, is that inhibition of PKR function efficient growth on noninducing dextrose (SD) medium
(Fig. 3B, left), only those harboring NS5A or K3L wereis mediated through a direct physical interaction with the
kinase (reviewed by Katze, 1993, 1995). We sought to able to sustain growth under conditions of PKR expres-
sion (Fig. 3B, right). Vector control transfectants exhib-determine if the NS5A– PKR interaction could similarly
result in an inhibition of PKR function. We first carried ited a severe slow growth phenotype consistent with
the growth suppressive activity associated with highout an in vitro analysis of PKR activity in the presence of
recombinant NS5A. Incubation of purified native PKR with levels of PKR expression (Fig. 3B) (Romano et al., 1995).
These results demonstrate that NS5A is sufficient torecombinant GST-NS5A from HCV-1a resulted in the spe-
cific inhibition of both PKR autophosphorylation and reverse PKR-mediated growth suppression in yeast,
indicating that NS5A can directly repress PKR functionphosphorylation of an exogenous histone substrate (Fig.
3A). It is worth noting that as little as 0.2 pmol of NS5A in vivo. To confirm that PKR function was repressed in
the presence of NS5A, we determined the level of eIF-can inhibit 1.8 pmol of PKR. At present we cannot deter-
mine whether this results from a relatively small percent- 2a phosphorylation in the RY1-1 transfectants. Similar
to K3L, expression of NS5A resulted in approximatelyage of PKR being active or whether NS5A may function
at low levels due, perhaps, to disruption of higher order an 11-fold increase in the level of unphosphorylated
eIF-2a over that observed in control transfectants har-PKR dimers. We confirmed that the loss of PKR activity
was not due to degradation of PKR or NS5A-mediated boring the vector alone (Fig. 3C). While the majority of
the eIF-2a in these cells remained in the hyperphos-hydrolysis of ATP (data not shown). Furthermore, while
it is possible that the inhibition of PKR and histone phos- phorylated state, these results suggest that relatively
small changes in the overall level of eIF-2a phosphory-phorylation in our in vitro assay could be due to a GST-
NS5A-mediated phosphatase activity, we believe this to lation can nevertheless have dramatic effects on cell
growth. Taken together, these observations indicatebe unlikely since NS5A does not possess any structural
attributes indicative of phosphatase function. Equal mo- that NS5A, through a direct interaction with PKR, can
repress PKR function in vivo, resulting in alterationslar levels of GST had no effect upon PKR activity (Fig.
3A, lanes 6–9). Thus, similar to the action of other virally in the phosphorylation state of the PKR substrate,
eIF-2a.encoded PKR inhibitory proteins, NS5A can specifically
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FIG. 3. NS5A represses PKR function. (A) Recombinant NS5A inhibits PKR activity in vitro. Purified native PKR (1.8 pmol) was preincubated
with buffer (lane 1) or increasing amounts of recombinant purified GST-NS5A (HCV 1a, lanes 2 – 5) or GST (lanes 6 – 9) and assayed for in vitro
kinase activity in the presence of histone H2a substrate. After termination of kinase reactions, phosphorylated products were separated by
12.5% SDS – PAGE and visualized by autoradiography of the dried gel. Arrows indicate the positions of PKR and histones. The molar amounts
of input GST-NS5A or GST proteins were 0.2 pmol (lanes 2 and 6), 0.4 pmol (lanes 3 and 7), 0.8 pmol (lanes 4 and 8), and 1.2 pmol (lanes 5
and 9). (B) NS5A reverses PKR-mediated growth suppression in yeast. Yeast strain RY1-1 was transfected with the 2m yeast expression
constructs pYES2-NS5A (NS5A; from HCV-1a) or pEMBLYex4-K3L (vaccinia virus K3L; positive control) or the negative control vectors pEM-
BLYex4 (pYex) and pYes2 (pYes). Transfectants were streaked onto minimal synthetic medium containing 2% dextrose (SD, left) or 10%
galactose/2% raffinose (SGAL, right) as the carbon source and scored for growth. SGAL plate represents 5 days of growth. (C) eIF-2a
phosphorylation analysis. Extracts from RY1-1 yeast harboring the vector control plasmid pYes2 (lane 1), NS5A (lane 2), or K3L (control; lane
3) were separated by isoelectric focusing and subjected to immunoblot analysis with an antiserum to yeast eIF-2a. Arrows indicate the
positions of eIF-2a phosphorylated on basal sites only (lower band) and eIF-2a phosphorylated on Ser 51, the site of phosphorylation by PKR
(upper band). The levels of basally phosphorylated eIF-2a relative to total were quantitated by scanning laser densitometry and are: vector,
0.9%; NS5A, 11.2%; and K3L, 11.7%. (D) NS5A stimulates protein synthesis in mammalian cells. COS1 cells expressing the SEAP reporter
protein were cotransfected with 10 mg of the control vector, pcDNA3.1/His (vector), or 10 mg plasmid DNA containing pcDNA3.1/His and
titrating amounts (indicated in mg) of pcDNA3.1/His-NS5A. SEAP activity was measured from the supernatant of each transfection culture and
is shown as the percentage of SEAP activity relative to that of control cells harboring the vector alone, which was normalized to 100%. (Bottom)
Expression of NS5A from COS1 cells transfected with vector DNA (vector) or 1, 2, 4, and 6 mg of pcDNA3.1/His-NS5A, as detected by immunoblot
analysis using a-NS5 sera. Each lane represents 50 mg of extract electrophoresed from 106 cells.
We next sought to determine if NS5A could similarly of protein synthesis in mammalian cells, we tested
the ability of NS5A to stimulate protein synthesis inregulate PKR within mammalian cells. Through repres-
sion of the eIF-2a-phosphorylating activity of PKR, tran- transfected COS1 cells using a secreted embryonic
alkaline phosphatase (SEAP) reporter assay (Berger etsient inhibition of PKR in mammalian cells results in a
net increase in the level of protein synthesis. Reflecting al., 1988). Coexpression of SEAP and NS5A (HCV-1a)
in COS1 cells resulted in greater than a 300% stimula-this effect of PKR inhibition, negative regulators of PKR
can stimulate protein synthesis above basal levels tion of protein synthesis over SEAP/vector cotransfec-
tants (Fig. 3D). Thus, similar to other PKR-inhibitorywhen introduced into mammalian cells (Svensson and
Akusjarvi, 1985; Seliger et al., 1992; Kaufman and Mur- molecules, including adenovirus VAI RNA, P58IPK and
reovirus s3 protein (Svensson and Akusjarvi, 1985; Sel-tha, 1987; Giantini and Shatkin, 1989; Tang et al., 1996).
To determine if NS5A expression could alter the level iger et al., 1992; Kaufman and Murtha, 1987; Giantini
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FIG. 4. Requirement of the ISDR region of NS5A for PKR interaction and repression of PKR function. (A) The ISDR of NS5A is required for
interaction with PKR in vivo. Yeast expressing the AD (AD-vector) or AD-PKR K296R (AD-PKR) were transfected with constructs expressing BD-
NS5A; BD-DISDR, which lacks the entire NS5A ISDR region (Fig. 1A); or BD-vector (bottom row). Both NS5A constructs were derived from HCV-1a.
Transfected yeast were replica plated onto /His (left panel) and 0His medium (right) and assayed for growth as described under Materials and
Methods. Two-hybrid protein interaction was defined as specific growth on 0His medium. (B) Expression of NS5A GAL4-fusion constructs. Extracts
from COS1 cells transfected with pcDNA3.1/His-NS5A (NS5A control; lane 1) or yeast cells with pBD (BD-vector; lane 2), pBD-DISDR (DISDR; lane
3), or pBD-NS5A (BD-NS5A; lane 4) were subjected to immunoblot analysis using a-NS5 sera. (Bottom) The corresponding expression of yeast
superoxide dismutase (SOD) using a-SOD sera as determined from the same blot and included to control for variations in extract protein concentra-
tions. By this method we determined that both BD-DISDR and BD-NS5A were expressed to the same levels. The apparent differences seen on the
blot reflect a threefold difference in protein concentration between the two extracts. Gel standards are shown in kDa. (C) The ISDR of NS5A is
required for reversal of PKR-mediated growth suppression in yeast. Yeast strain RY1-1 harboring the expression constructs pYES2-NS5A (NS5A),
pYES2-DISDR (DISDR) or the negative control vector pYES2 (pYes), were streaked onto inducing medium containing 10% galactose/2% raffinose
(SGAL) and scored for growth. SGAL plate shown represents 6 days of growth. All transfectants grew when streaked onto noninducing SD medium
(data not shown).
and Shatkin, 1989; Tang et al., 1996), NS5A can stimu- which similarly lack the ISDR, failed to interact with PKR
in this assay (data not shown). In contrast, BD-NS5Alate protein synthesis in mammalian cells, likely
through a direct inhibitory effect upon PKR. specifically interacted with AD-PKR K296R (Fig. 4A). Dele-
tion of the ISDR from NS5A could conceivably render the
The NS5A ISDR is required for interaction with PKR mutant protein unstable and unavailable to interact with
and repression of PKR function in vivo PKR. However, immunoblot analysis demonstrated that
both BD-NS5A and -DISDR constructs were efficientlyInhibition of PKR in infected mammalian cells may be
expressed in yeast transfectants (Fig. 4B). By standardiz-one mechanism by which HCV mediates resistance to
ing protein loading, using antibody to yeast superoxideIFN. Correlation of IFN sensitivity with mutations within
dismutase, we quantified NS5A levels and determinedthe ISDR of NS5A suggested that the ISDR may play a
that both BD-DISDR and BD-NS5A were expressed torole in mediating the IFN-resistant phenotype of HCV. A
approximately the same levels (see the legend to Fig.key question remaining was whether or not the ISDR
4B). The possibility remains, however, that deletion ofcontributed to the ability of NS5A to bind to and inhibit
the ISDR may render NS5A conformationally constrained,PKR. To begin to determine the requirement for the ISDR
thus precluding interaction with PKR. Collectively, thesein the NS5A–PKR interaction, we compared the ability of
results suggest that the ISDR of NS5A is necessary forBD-NS5A and of a BD-NS5A ISDR-deletion mutant de-
interaction with PKR and that deletion of the ISDR mayrived from HCV-1a (BD-DISDR; Fig. 1A) to bind to AD-
render NS5A nonfunctional in vivo. We thereby comparedPKR K296R in vivo. BD-DISDR failed to mediate interac-
the ability of NS5A and the DISDR mutant to reverse thetion with AD-PKR K296R in the yeast 2-hybrid assay (Fig.
4A). We also found that the N-terminal 236 aa of NS5A, PKR-mediated slow growth phenotype in yeast. Coex-
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pression of DISDR with PKR in yeast strain RY1-1 failed of NS5A. It is tempting to speculate that specific muta-
tions in the ISDR, which may exist within an HCV quasi-to reverse PKR-mediated growth repression while ex-
pression of NS5A specifically restored growth in the species population, may compromise the ability of
NS5A to repress PKR. Though beyond the scope of thetransfected yeast clones (Fig. 4C). These results, taken
together, indicate that the NS5A ISDR is required for current report, a broader analysis of NS5A proteins
from IFN-resistant and IFN-sensitive HCV strains isinteraction with and inhibition of PKR activity in vivo.
required to correlate ISDR structure with the ability to
repress PKR. NS5A from both HCV-1a and -1b pos-DISCUSSION
sessed the ability to bind to PKR, suggesting the possi-
bility that PKR regulation may be a common mecha-The cellular IFN response is one of the body’s first
defense mechanisms to prevent the establishment of vi- nism by which both genotypes may mediate IFN resis-
tance. This is supported by the high response rate toral infection (Sen and Lengyel, 1992; Sen and Ransohoff,
1993). The ability of a given animal virus to establish a IFN therapy exhibited in HCV genotypes 2 – 4, which
lack a consensus ISDR (S. Polyak and D. Gretch, un-productive infection depends in part on the ability of the
virus to circumvent the IFN response, which includes the published observations). We suggest that combinato-
rial therapeutic strategies designed to block thetranscriptional induction and functional activation of PKR.
Indeed, we have found in many cases that the ability of NS5A – PKR interaction may increase the efficacy of
IFN treatment of an HCV-1a or -1b infection.a virus to establish a productive infection correlates well
with its ability to repress PKR function (Katze, 1993, 1995). We have shown that HCV NS5A from both IFN-resis-
tant HCV-1a and HCV-1b strains can specifically interactResults presented in this study demonstrate that HCV
similarly encodes a mechanism to repress PKR. We pro- with and inhibit the activity of PKR, also raising the possi-
bility that NS5A could be a PKR substrate. However, ourpose that the HCV NS5A protein functions to directly
repress PKR, thus preventing, at least in part, the antiviral preliminary results argue against this as we have not
found that PKR can phosphorylate NS5A in our in vitroeffects of IFN on HCV replication.
In addition to its antiviral properties, PKR plays a func- assay. Moreover, while NS5A does reside in the cell as
a phosphoprotein (Tanji et al., 1995; Kaneko et al., 1994),tional role in signal transduction pathways leading to
the transcriptional regulation of gene expression and the we currently do not know what role, if any, that NS5A
phosphorylation plays in mediating NS5A function or in-induction of apoptosis (reviewed by Proud, 1995). Thus,
inhibitors of PKR can have profound effects on gene ex- teraction with PKR. Importantly, NS5A binds to a region
of PKR (aa 244–366; Fig 1B) which participates in thepression which may ultimately be detrimental to the cell.
Indeed, previous studies from our laboratory and others formation of active PKR dimers (Patel et al., 1995). This
region includes a regulatory autophosphorylation site, T-have shown that inhibitors of PKR can induce oncogene-
sis (Koromilas et al., 1992; Meurs et al., 1993; Barber et 258, followed by protein kinase catalytic domain conser-
vation regions I–V (Taylor et al., 1996; Hanks et al., 1988).al., 1995). While other mechanisms of oncogenesis may
exist within an HCV-infected cell, including those specific Based upon the known crystal structure of the catalytic
domain of related protein kinases, NS5A would occupyto the transforming properties of the NS3 and viral core
proteins (Sakamuro et al., 1995; Ray et al., 1996), it is a critical region within the small lobe and catalytic cleft
of the PKR catalytic domain that is involved in nucleotidetempting to speculate that the NS5A-mediated inhibition
of PKR may lead to malignant transformation of the in- binding and catalysis (Bossemeyer, 1995; Taylor et al.,
1993). Significantly, among various protein kinases thisfected hepatocyte, perhaps reflecting the high frequency
of hepatocellular carcinomas within the HCV-infected region of the catalytic domain appears to be the target
for interaction by kinase-regulatory proteins, includingpopulation.
Molecular epidemiological studies have revealed that between the cyclic AMP-dependent protein kinase
and its RI regulatory subunit, as well as the cyclin/cyclin-that the HCV genome exhibits a significant level of
heterogeneity within HCV infected individuals as a re- dependent kinase interactions (reviewed in Bossemeyer,
1995; Taylor et al., 1993). Unlike the vaccinia virus K3Lsult of the high frequency of mutations that occur dur-
ing viral replication (Bukh et al., 1995). Referred to as and adenovirus VAI gene products, which inhibit PKR by
functioning as a pseudosubstrate and competitive inhibi-viral quasispecies, the population of HCV genomes
within an infected individual may influence the out- tor of activator–dsRNA binding, respectively (Katze, 1993,
1995), we propose that NS5A may interfere with eventscome of IFN therapy. Indeed, this is supported by the
recent studies which correlate mutations in the ISDR leading to activation and catalysis by directly interfering
with dimerization, autophosphorylation, and/or stepsof the HCV-1b NS5A protein with IFN sensitivity (Eno-
moto et al., 1995, 1996). Importantly, our data have within the catalytic process. It is worth noting that the
NS5A-interactive region of PKR includes the domainindicated that the ISDR was required for both PKR bind-
ing and functional PKR repression, possibly defining a which binds the cellular PKR inhibitor, P58IPK (Fig. 1B)
(Gale et al., 1996). The localization of both the P58IPK-critical role for this region in mediating in vivo function
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sequences amplified from the 5* non-coding region. J. Gen. Virol. 76,and the NS5A-interactive sites to overlapping domains
1197–1204.of PKR reflects the importance of this region for kinase
Dever, T. E., Chen, J. J., Barber, G. N., Cigan, A. M., Feng, L., Donahue,function and suggests that these divergent inhibitors may T. F., London, I. M., Katze, M. G., and Hinnebusch, A. G. (1993). Mam-
repress PKR by similar mechanisms. malian eIF-2a kinases functionally substitute for GCN2 and stimulate
GCN4 translation in yeast. Proc. Natl. Acad. Sci. USA. 90, 4616–
4620.
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